CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

The m6A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis

Open access

Published version of a preprint

Abstract

Evidence for the involvement of N 6 -Methyladenosine (m 6 A) modification in the etiology and progression of liver fibrosis has emerged and holds promise as a therapeutic target. Insulin-like growth factor 2 (IGF2) mRNA-binding protein 2 (IGF2BP2) is a newly identified m 6 A-binding protein that functions to enhance mRNA stability and translation. However, its role as an m 6 A-binding protein in liver fibrosis remains elusive. Here, we observed that IGF2BP2 is highly expressed in liver fibrosis and activated hepatic stellate cells (HSCs), and inhibition of IGF2BP2 protects against HSCs activation and liver fibrogenesis. Mechanistically, as an m 6 A-binding protein, IGF2BP2 regulates the expression of Aldolase A ( ALDOA ), a key target in the glycolytic metabolic pathway, which in turn regulates HSCs activation. Furthermore, we observed that active glycolytic metabolism in activated HSCs generates large amounts of lactate as a substrate for histone lactylation. Importantly, histone lactylation transforms the activation phenotype of HSCs. In conclusion, our findings reveal the essential role of IGF2BP2 in liver fibrosis by regulating glycolytic metabolism and highlight the potential of targeting IGF2BP2 as a therapeutic for liver fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-024-06509-9

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 IGF2BP2 expression is elevated in liver fibrosis and cirrhosis. A IGF2BP2 expression in liver fibrosis and cirrhosis from the GEO database. (a) Igf2bp2 expression in CCl4-induced liver fibrosis and normal control from GSE55747. b–d IGF2BP2 expression in liver cirrhosis and normal control from GSE102383, GSE25097, and GSE6764. e IGF2BP2 expression in patients with Scheuer scores S0-1 and S2-4 from GSE84044. f IGF2BP2 expression in cirrhotic patients who develop HCC and those who do not develop HCC from GSE15654. g IGF2BP2 expression in cirrhotic patients with good or poor prognosis from GSE15654. B IGF2BP2 expression in cirrhosis retrieved from the Human Liver Proteome Database. C–E Correlation analysis of IGF2BP2 expression with ACTA2 and COL1α1 expression in cirrhotic samples from GSE25097 (n = 40) and GSE15654 (n = 216). Representative H&E staining and Masson’s trichrome staining images (F) and bar plot (G) in CCl4-induced fibrotic livers of mice and livers of human patients with cirrhosis (scale bars, 100 µm). H Igf2bp2, Acta2, and Col1α1 mRNA expression in CCl4-induced fibrotic livers of mice. I Correlation analysis of Igf2bp2 mRNA expression with Acta2 mRNA expression and Col1α1 mRNA expression. Levels of IGF2BP2 in CCl4-induced fibrotic livers of mice and livers of human patients with cirrhosis revealed by immunoblotting (J) and bar plot (K). L Serum levels of IGF2BP2 in cirrhotic patients (n = 46) and healthy donors (n = 24). M The receiver operating characteristic (ROC) curve demonstrates the efficacy of IGF2BP2 combined with alanine transaminase (ALT) in predicting cirrhosis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 1 IGF2BP2 expression is elevated in liver fibrosis and cirrhosis. A IGF2BP2 expression in liver fibrosis and cirrhosis from the GEO database. (a) Igf2bp2 expression in CCl4-induced liver fibrosis and normal control from GSE55747. b–d IGF2BP2 expression in liver cirrhosis and normal control from GSE102383, GSE25097, and GSE6764. e IGF2BP2 expression in patients with Scheuer scores S0-1 and S2-4 from GSE84044. f IGF2BP2 expression in cirrhotic patients who develop HCC and those who do not develop HCC from GSE15654. g IGF2BP2 expression in cirrhotic patients with good or poor prognosis from GSE15654. B IGF2BP2 expression in cirrhosis retrieved from the Human Liver Proteome Database. C–E Correlation analysis of IGF2BP2 expression with ACTA2 and COL1α1 expression in cirrhotic samples from GSE25097 (n = 40) and GSE15654 (n = 216). Representative H&E staining and Masson’s trichrome staining images (F) and bar plot (G) in CCl4-induced fibrotic livers of mice and livers of human patients with cirrhosis (scale bars, 100 µm). H Igf2bp2, Acta2, and Col1α1 mRNA expression in CCl4-induced fibrotic livers of mice. I Correlation analysis of Igf2bp2 mRNA expression with Acta2 mRNA expression and Col1α1 mRNA expression. Levels of IGF2BP2 in CCl4-induced fibrotic livers of mice and livers of human patients with cirrhosis revealed by immunoblotting (J) and bar plot (K). L Serum levels of IGF2BP2 in cirrhotic patients (n = 46) and healthy donors (n = 24). M The receiver operating characteristic (ROC) curve demonstrates the efficacy of IGF2BP2 combined with alanine transaminase (ALT) in predicting cirrhosis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Fig. 2 Inhibition of IGF2BP2 ameliorates CCl4-induced liver fibrosis. A Schematic illustrating of the experimental design of AAV-shIgf2bp2 for the treatment of CCl4-induced liver fibrosis in mice. B Expression of Igf2bp2 in mouse liver samples treated in according to (A) (n = 4). Representative images (C) and bar plot (D, E) of H&E staining (upper), masson’s trichrome staining (middle) and sirius red staining (bottom) in mouse liver sections treated according to (A) (n = 6, scale bar, 100 µm). Representative images (F) and bar plot (G) of α-SMA expression (n = 3, scale bar, 100 µm) visualized by immunofluorescence in mouse liver sections treated according to (A). Serum levels of ALT (H) and AST (I) in mice treated according to (A). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 2 Inhibition of IGF2BP2 ameliorates CCl4-induced liver fibrosis. A Schematic illustrating of the experimental design of AAV-shIgf2bp2 for the treatment of CCl4-induced liver fibrosis in mice. B Expression of Igf2bp2 in mouse liver samples treated in according to (A) (n = 4). Representative images (C) and bar plot (D, E) of H&E staining (upper), masson’s trichrome staining (middle) and sirius red staining (bottom) in mouse liver sections treated according to (A) (n = 6, scale bar, 100 µm). Representative images (F) and bar plot (G) of α-SMA expression (n = 3, scale bar, 100 µm) visualized by immunofluorescence in mouse liver sections treated according to (A). Serum levels of ALT (H) and AST (I) in mice treated according to (A). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Fig. 3 Inhibition of IGF2BP2 blocks HSCs activation in vitro. qRT-PCR (A) and immunoblotting (B) confirmed effective IGF2BP2 KD by shRNA in LX-2 cells. Representative images (C) and bar plot (D–F) of cell migration assays (upper, scale bar, 50 µm), EdU cell proliferation assays (middle, scale bar, 20 µm), and immunofluorescence (bottom, scale bar, 20 µm) in IGF2BP2 KD LX-2 cells, and shNC-transfected LX-2 cells treated with TGF-β1 as a positive control. Representative images (G) and bar plot (H) of oil red O staining in IGF2BP2 KD LX-2 cells treated or untreated with TGF-β1 for 24 h (scale bar, 20 µm). Representative images (I) and bar graphs (J) of oil red O staining of LX-2 cells pretreated with JX5 (blank, 10 µM, 30 µM) for 8 h, followed by treatment or untreatment with TGF-β1 for 24 h (scale bar, 20 µm). K ACTA2 and COL1α1 mRNA expression in LX-2 cells pretreated with JX5 (blank, 10 µM, 30 µM) for 8 h, followed by treatment with TGF-β1 for different time points (0, 6, 12 h). L ACTA2 mRNA expression in LX-2 cells cultured with 10% FBS treated with JX5 (blank, 10, 30 µM) for 1 h, and LX-2 cells cultured with 2% FBS as control. n.s., not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 3 Inhibition of IGF2BP2 blocks HSCs activation in vitro. qRT-PCR (A) and immunoblotting (B) confirmed effective IGF2BP2 KD by shRNA in LX-2 cells. Representative images (C) and bar plot (D–F) of cell migration assays (upper, scale bar, 50 µm), EdU cell proliferation assays (middle, scale bar, 20 µm), and immunofluorescence (bottom, scale bar, 20 µm) in IGF2BP2 KD LX-2 cells, and shNC-transfected LX-2 cells treated with TGF-β1 as a positive control. Representative images (G) and bar plot (H) of oil red O staining in IGF2BP2 KD LX-2 cells treated or untreated with TGF-β1 for 24 h (scale bar, 20 µm). Representative images (I) and bar graphs (J) of oil red O staining of LX-2 cells pretreated with JX5 (blank, 10 µM, 30 µM) for 8 h, followed by treatment or untreatment with TGF-β1 for 24 h (scale bar, 20 µm). K ACTA2 and COL1α1 mRNA expression in LX-2 cells pretreated with JX5 (blank, 10 µM, 30 µM) for 8 h, followed by treatment with TGF-β1 for different time points (0, 6, 12 h). L ACTA2 mRNA expression in LX-2 cells cultured with 10% FBS treated with JX5 (blank, 10, 30 µM) for 1 h, and LX-2 cells cultured with 2% FBS as control. n.s., not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Fig. 4 IGF2BP2 is involved in the ECM pathway and glycolytic metabolic processes. A Performing GSEA enrichment analysis in IGF2BP2 KD LX-2 cells to demonstrate enrichment signaling pathways or biological processes involved in IGF2BP2. B Bubble diagram showing KEGG enrichment analysis in IGF2BP2 KD LX-2 cells. The y-axis is for KEGG terms. The size and color of the bubbles represent the number and significance of genes associated with the term, respectively. C Heatmap representation of glycolysis/gluconeogenesis processes-related genes differentially expressed in IGF2BP2 KD LX-2 cells. The color bar indicates the value of the Z-transformed expression.
Fig. 4 IGF2BP2 is involved in the ECM pathway and glycolytic metabolic processes. A Performing GSEA enrichment analysis in IGF2BP2 KD LX-2 cells to demonstrate enrichment signaling pathways or biological processes involved in IGF2BP2. B Bubble diagram showing KEGG enrichment analysis in IGF2BP2 KD LX-2 cells. The y-axis is for KEGG terms. The size and color of the bubbles represent the number and significance of genes associated with the term, respectively. C Heatmap representation of glycolysis/gluconeogenesis processes-related genes differentially expressed in IGF2BP2 KD LX-2 cells. The color bar indicates the value of the Z-transformed expression.CC BY · PubMed Central
Fig. 5 IGF2BP2 regulates glycolytic metabolism by increasing ALDOA expression. A Venn diagram showing screening strategies for candidate downstream targets of IGF2BP2. B Bubble diagram showing Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of candidate target genes screened by (A). The y-axis is for KEGG terms. The size and color of the bubbles represent the number and significance of genes associated with the term, respectively. C Expression of initially selected downstream targets (PGK1, LDHB, ENO1, and ALDOA) of IGF2BP2 in the GSE90639 dataset. D Expression of selected downstream targets (PGK1, LDHB, ENO1, and ALDOA) detected in RNA-seq and qRT-PCR, and metabolic schematic of selected targets in the glycolytic pathway. E RIP assay using IGF2BP2 antibody in IGF2BP2 KD or control LX-2 cells. F RIP assay using m6A antibody in LX-2 cells. G ALDOA mRNA half-life in IGF2BP2 KD or control LX-2 cells. H Interactions between IGF2BP2 and ALDOA were predicted based on POSTAR3 (http://postar.ncrnalab.org). I High-confidence m6A modification sites on ALDOA were predicted from SRAMP (www.cuilab.cn/). J ALDOA expression in CCl4-induced liver fibrosis and normal control from GSE55747. K ALDOA expression in liver cirrhosis and normal control from GSE6764. L, M Correlation analysis of IGF2BP2 expression with ALDOA expression in cirrhotic samples from GSE25097 (n = 40) and GSE15654 (n = 216). N-R Measurement of lactate levels (N), α-SMA expression, and migration capacity (upper of Fig. 5P, scale bar, 50 µm) in LX-2 cells after co-transfection of ALDOA overexpression vector (OE-ALDOA) or control vector (Vector) in IGF2BP2 KD (shIGF2BP2) and control (shNC) cells. α-SMA expression was measured using immunoblotting (O) and immunofluorescence (bottom of Fig. 5P, scale bar, 20 µm). There are bar graphs showing the migration capacity (Q) and the fluorescence intensity of α-SMA expression (R) in LX-2 cells. n.s. not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 5 IGF2BP2 regulates glycolytic metabolism by increasing ALDOA expression. A Venn diagram showing screening strategies for candidate downstream targets of IGF2BP2. B Bubble diagram showing Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of candidate target genes screened by (A). The y-axis is for KEGG terms. The size and color of the bubbles represent the number and significance of genes associated with the term, respectively. C Expression of initially selected downstream targets (PGK1, LDHB, ENO1, and ALDOA) of IGF2BP2 in the GSE90639 dataset. D Expression of selected downstream targets (PGK1, LDHB, ENO1, and ALDOA) detected in RNA-seq and qRT-PCR, and metabolic schematic of selected targets in the glycolytic pathway. E RIP assay using IGF2BP2 antibody in IGF2BP2 KD or control LX-2 cells. F RIP assay using m6A antibody in LX-2 cells. G ALDOA mRNA half-life in IGF2BP2 KD or control LX-2 cells. H Interactions between IGF2BP2 and ALDOA were predicted based on POSTAR3 (http://postar.ncrnalab.org). I High-confidence m6A modification sites on ALDOA were predicted from SRAMP (www.cuilab.cn/). J ALDOA expression in CCl4-induced liver fibrosis and normal control from GSE55747. K ALDOA expression in liver cirrhosis and normal control from GSE6764. L, M Correlation analysis of IGF2BP2 expression with ALDOA expression in cirrhotic samples from GSE25097 (n = 40) and GSE15654 (n = 216). N-R Measurement of lactate levels (N), α-SMA expression, and migration capacity (upper of Fig. 5P, scale bar, 50 µm) in LX-2 cells after co-transfection of ALDOA overexpression vector (OE-ALDOA) or control vector (Vector) in IGF2BP2 KD (shIGF2BP2) and control (shNC) cells. α-SMA expression was measured using immunoblotting (O) and immunofluorescence (bottom of Fig. 5P, scale bar, 20 µm). There are bar graphs showing the migration capacity (Q) and the fluorescence intensity of α-SMA expression (R) in LX-2 cells. n.s. not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Fig. 6 Histone lactylation is essential in HSCs activation. A Global lactylation levels in liver sections from CCl4-induced liver fibrosis mice and healthy mice were visualized by immunofluorescence (scale bar, 100 µm). B Immunoblotting showing global lactylation and H3K18la levels after TGF-β1-induced LX-2 cells for different times (0, 6, 12, 24 h). C Immunoblotting shows global lactylation and H3K18la levels in LX-2 cells with IGF2BP2 KD. D Immunoblotting shows global lactylation and H3K18la levels in LX-2 cells treated with different concentrations of lactate, 2-DG, or rotenone for 24 h. Representative images (E) and bar graphs (F) showing lipid droplets, migration capacity, cell proliferation, and α-SMA expression after treatment of LX-2 cells with TGF-β1, 2-DG, or lactate, as detected by oil red O staining, cell migration assays, EdU cell proliferation assays, and immunofluorescence, respectively. G Immunoblotting showed expression of α-SMA at 10 mmol/L exogenous lactate supplementation for different times (6 h, 12 h, 24 h). H qRT-PCR verified the expression of ACTA2 at 1 h of 2-DG, lactate treatment. Representative images (upper of I, scale bar, 50 µm) and bar plot (J) showing cell migration in LX-2 cells silenced for LDHA and LDHB. Representative images showing α-SMA expression (bottom of Fig. 6I, scale bar, 20 µm) in LX-2 cells silenced for LDHA and LDHB. K Immunoblotting shows α-SMA expression in LX-2 cells silenced for LDHA and LDHB. n.s. not significant; *P < 0.05, **P < 0.01, ****P < 0.0001.
Fig. 6 Histone lactylation is essential in HSCs activation. A Global lactylation levels in liver sections from CCl4-induced liver fibrosis mice and healthy mice were visualized by immunofluorescence (scale bar, 100 µm). B Immunoblotting showing global lactylation and H3K18la levels after TGF-β1-induced LX-2 cells for different times (0, 6, 12, 24 h). C Immunoblotting shows global lactylation and H3K18la levels in LX-2 cells with IGF2BP2 KD. D Immunoblotting shows global lactylation and H3K18la levels in LX-2 cells treated with different concentrations of lactate, 2-DG, or rotenone for 24 h. Representative images (E) and bar graphs (F) showing lipid droplets, migration capacity, cell proliferation, and α-SMA expression after treatment of LX-2 cells with TGF-β1, 2-DG, or lactate, as detected by oil red O staining, cell migration assays, EdU cell proliferation assays, and immunofluorescence, respectively. G Immunoblotting showed expression of α-SMA at 10 mmol/L exogenous lactate supplementation for different times (6 h, 12 h, 24 h). H qRT-PCR verified the expression of ACTA2 at 1 h of 2-DG, lactate treatment. Representative images (upper of I, scale bar, 50 µm) and bar plot (J) showing cell migration in LX-2 cells silenced for LDHA and LDHB. Representative images showing α-SMA expression (bottom of Fig. 6I, scale bar, 20 µm) in LX-2 cells silenced for LDHA and LDHB. K Immunoblotting shows α-SMA expression in LX-2 cells silenced for LDHA and LDHB. n.s. not significant; *P < 0.05, **P < 0.01, ****P < 0.0001.CC BY · PubMed Central
Fig. 7 Inhibition of histone lactylation ameliorates liver fibrosis in vivo. A Schematic illustration of the experimental design of 2-DG (1000 mg/kg) for the treatment of CCl4-induced liver fibrosis in mice. B Lactate levels in the serum of mice treated according to (A) (n = 6). Representative images (C) and bar plot (D, E) of H&E staining (upper), Masson’s trichrome staining (middle), and sirius red staining (bottom) in mouse liver sections treated according to (A) (n = 6, scale bar, 100 µm). Representative images (F) and bar plot (G) of α-SMA expression (upper, n = 3, scale bar, 100 µm) visualized by immunofluorescence in mouse liver sections treated according to (A). Serum levels of ALT (H) and AST (I) in mice treated according to (A). **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 7 Inhibition of histone lactylation ameliorates liver fibrosis in vivo. A Schematic illustration of the experimental design of 2-DG (1000 mg/kg) for the treatment of CCl4-induced liver fibrosis in mice. B Lactate levels in the serum of mice treated according to (A) (n = 6). Representative images (C) and bar plot (D, E) of H&E staining (upper), Masson’s trichrome staining (middle), and sirius red staining (bottom) in mouse liver sections treated according to (A) (n = 6, scale bar, 100 µm). Representative images (F) and bar plot (G) of α-SMA expression (upper, n = 3, scale bar, 100 µm) visualized by immunofluorescence in mouse liver sections treated according to (A). Serum levels of ALT (H) and AST (I) in mice treated according to (A). **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Fig. 8 Schematic model of the mechanism of IGF2BP2 and histone lactylation in liver fibrosis. IGF2BP2 is highly activated in fibrotic livers of mice. Mechanistically, IGF2BP2 enhances the stability of the m6A-modified transcript ALDOA in the glycolytic metabolic pathway, which is crucial for HSCs activation. In addition, lactate produced by activated HSCs via the glycolytic pathway serves as a substrate for lactylation, which plays an essential role in the activation of HSCs. Created with BioRender.com.
Fig. 8 Schematic model of the mechanism of IGF2BP2 and histone lactylation in liver fibrosis. IGF2BP2 is highly activated in fibrotic livers of mice. Mechanistically, IGF2BP2 enhances the stability of the m6A-modified transcript ALDOA in the glycolytic metabolic pathway, which is crucial for HSCs activation. In addition, lactate produced by activated HSCs via the glycolytic pathway serves as a substrate for lactylation, which plays an essential role in the activation of HSCs. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 92

Metadata

Authors
Zhou, Y., Yan, J., Huang, H., Liu, L., Ren, L., Hu, J., Jiang, X., Zheng, Y., Xu, L., Zhong, F., & Li, X.
Affiliations
  • Lanzhou University (CN)
  • First Hospital of Lanzhou University (CN)
Corresponding author
Li, Xun
Venue
Cell Death & Disease
Published
2024-03-05
Volume
15
Issue
3
Pages
189-189
ISSN
2041-4889 (ISSN-L)
OpenAlex
W4392457888
Cited by
92
References
49
Citations by year
2026: 37 · 2025: 43 · 2024: 11
FWCI
12.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82060119)
  • Natural Science Foundation of Gansu Province (23JRRA0924)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
IGF2BP2, N6-methyladenosine, m6A RNA methylation, liver fibrosis, hepatic stellate cell activation, glycolytic metabolism, aldolase A, histone lactylation, lactate, mRNA-binding proteins, therapeutic target
MeSH terms
Histones, Humans, Liver Cirrhosis, RNA-Binding Proteins, Lactic Acid, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The m6A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis. https://app.cochat.ai/papers/10.1038/s41419-024-06509-9
The paper
Zhou, Y., Yan, J., Huang, H., Liu, L., Ren, L., Hu, J., Jiang, X., Zheng, Y., Xu, L., Zhong, F., & Li, X. (2024). The m6A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis. Cell Death & Disease. https://doi.org/10.1038/s41419-024-06509-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.